Diarrhea clinical trials at University of California Health
3 in progress, 1 open to eligible people
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
open to eligible people ages 12 years and up
The overall objective of the RESTORATiVE303 study is to evaluate the safety and the Clostridioides difficile infection (CDI) recurrence rate at Week 8 in participants who receive a 14-day course of VE303 or matching placebo. The objectives and endpoints are identical for Stage 1 (recurrent CDI) and Stage 2 (high-risk primary CDI).
at UCLA
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
Sorry, in progress, not accepting new patients
This phase II trial studies how well isatuximab works in treating patients with primary amyloidosis that has come back or does not respond to treatment. Monoclonal antibodies, such as isatuximab, may interfere with the ability of cancer cells to grow and spread.
at UC Davis UC Irvine
PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
Sorry, in progress, not accepting new patients
The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and exploratory dose response of paltusotine treatment in subjects with carcinoid syndrome. This study consists of a Randomized Treatment Phase followed by an Open-Label Extension (OLE) Phase.
at UCLA
Last updated: